Poor CD4 Cell Recovery on ART Predicts Non-AIDS Death

People with HIV who have poor CD4 T-cell recovery despite viral suppression on antiretroviral therapy (ART) have a higher risk of death due to non-AIDS-related causes, but so do their parents, suggesting a genetic factor may be involved in T-cell regeneration, according to a Danish study described in the November 28, 2012, advance online edition of AIDS.


Higher Dose Flu Vaccine Works Better for People with HIV

HIV positive people who received a quadruple dose of a trivalent seasonal influenza vaccine produced more protective antibodies without a significant increase in side effects, researchers reported in the January 1, 2013, Annals of Internal Medicine.

New HIV Infections Down for U.S. Black Women, Still Rising for Young Gay Men

HIV incidence continues to climb for young men who have sex with men (MSM) -- the group with the highest incidence -- showing a 22% increase between 2008 and 2010, according to new data from the Centers for Disease Control and Prevention (CDC). The rate fell by 21% among African-American women, however, representing the first-ever significant decline.


Naloxone Is Cost-effective Way to Prevent Heroin Overdose Deaths

Distributing naloxone more widely to heroin users would reduce the number of deaths due to overdose and would be a cost-effective intervention, according to a mathematical model described in the January 1, 2013,Annals of Internal Medicine. Providing naloxone to prescription opiate users would prevent even more deaths.


WHO, UNAIDS, NSWP Release Guidelines to Reduce Sex Workers' HIV Burden

A report released by the World Health Organization (WHO) and collaborating organizations earlier this month proposes guidelines for public health and legal systems to reduce the vulnerability of sex workers to HIV and other sexually transmitted infections (STIs). Sex worker advocates generally favored the recommendations, but raised concerns about presumptive antibiotic treatment.


FDA Approves Diarrhea Drug Crofelemer for People with HIV/AIDS

On December 31, the U.S. Food and Drug Administration (FDA) approved crofelemer (brand name Fulyzaq) for treatment of diarrhea in people with HIV/AIDS on antiretroviral therapy (ART) -- the first approved medication for this indication.


Top 12 HIV and Hepatitis Stories of 2012

In our last issue for 2012, reviews some the year's major HIV and viral hepatitis news highlights. On the HIV front, U.S. treatment guidelines recommended antiretroviral therapy (ART) for all HIV positive people, Truvada was approved for pre-exposure prophylaxis (PrEP), and HIV criminalization and cure research were highlighted at the International AIDS Conference in July. Promising findings were reported for several interferon-free oral regimens for hepatitis C, experimental tuberculosis (TB) drugs showed good results, and the Affordable Care Act remained on track.alt